Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Crescita Therapeutics Inc T.CTX

Alternate Symbol(s):  CRRTF

Crescita Therapeutics Inc. is a commercial dermatology company with in-house research and development (R&D) and manufacturing capabilities. It offers a portfolio of science-based non-prescription skincare products and early to commercial stage prescription products. It operates in three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. The Commercial Skincare segment manufactures and sells branded non-prescription skincare products for the Canadian and international markets. It also commercializes Pliaglis, NCTF Boost 135 HA, ART FILLER, and Obagi Medical in Canada. The Licensing and Royalties segment engaged in licensing the intellectual property related to Pliaglis or its transdermal delivery technologies. Manufacturing and Services segment engaged in the sale of topical products manufactured to client specifications under the Company’s contract development and manufacturing organization infrastructure, and product development services.


TSX:CTX - Post by User

Bullboard Posts
Comment by TheRock07on Nov 14, 2016 9:17pm
136 Views
Post# 25460261

RE:Cipher Selling US drug assets

RE:Cipher Selling US drug assetsThe thought just occurred to me that Crescita will launch Pliaglis in the US, Mexico and Canada in Q1 of 2017.

Earlier in one of my posts    (https://www.stockhouse.com/companies/bullboard?symbol=t.ctx&postid=25225970  ) , I estimated 2015 sales of pliaglis in the US, by Galderma at $18.5 million US.

In that year, Galderma added  a few salemen which were directly focussed on pushing US sales volumes.

But the sales effort was marginal.
With a dedicated sales force and effective marketing, Pliaglis could achieve its $50 million US sales target.

Pliaglis is a skin drug and Cipher has its US dermatology drug assets up for sale , if not the entire company.

Crescita's CFO recently ...coincident with the acquisition of Intega ,, left and joined Cipher.

That seems to be an odd move given that Cipher just announced its strategic iniatives.

Here is my take.
GUD will buy Ciphers Canadian drug assets ( $40 million in revenues ) coincident with Crescita's acquisition of Ciphers US assets.

GUD is already Crescita largest shareholder and has licensed some of Crescita dermatology products for international sales.
GUD's CEO was recently appointed to Crescita's BOD.

It makes so much common sense that I will go out on a limb and say that Crescita will one way or another acquire Ciphers US drug assets along with 28 detail salesmen and that Lemieux will return to Crescita as head of its US operations.
Bullboard Posts